

REFERENCES

- **Adams AC.(2008):** Mayo Clinic Essential Neurology. Rochester, MN: Mayo Clinic Scientific Press. pp. 152–154.pp. 322pp. 324–325.pp. 336.
- **Agnholt J, Kaltoft K.(2001):** Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine. 15:212–222.
- **Al Saieg N, Luzar MJ.(2006):** Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol. 33(6):1202–1204.
- **Alamanos Y, Drosos A A.(2005):** Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 4:130–136.
- **Amit Bar.(2008):**Or PAJCDACMSSLHKEWSGRJFMPNSSA Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Annals of Neurology. 63:395–400.
- **Aouba A, Pagnoux C, and Bienvenu B, et al.(2008):** Analysis of Wegener's Granulomatosis Responses to Rituximab: Current Evidence and Therapeutic Prospects. Clinical Reviews in Allergy and Immunology. 34:65–73.
- **Ardizzone S, Bianchi Porro G.(2002):** Inflammatory bowel disease: new insights into pathogenesis and therapy. J Intern Med. 252:475–496.
- **Atzeni F, Turiel M, and Capsoni F.(2005):** Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci. 1051:559–569.
- **Balanescu A, Radu E, and Nat R.(2005):** Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients. Int J Clin Pharmacol Res. 25:9–18.
- **Bauman SK, Huffnagle GB, Murphy JW.(2003):** Effects of tumor necrosis factor alpha on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the

anticryptococcal cell-mediated immune response. *Infect Immun.* 71:68–74.

- **Bensouda-Grimaldi L, Mulleman D, and Valat JP, et al.(2007):** Autret-Leca E. Adalimumab-associated multiple sclerosis. *J Rheumatol.* 34(1):239–240.
- **Beutler B.(2001):** Autoimmunity and apoptosis: the Crohn's connection. *Immunity.* 15:5–14.
- **Bourreille A, Doubremelle M, de la Bletiere DR, et al.(2003):** RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn's disease. *Scand J Gastroenterol.* 38:526–532.
- **Breedveld F, Agarwal S, Yin M, et al.(2007):** Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B-Cell Levels Do Not Correlate With Clinical Response. *J Clin Pharmacol.* 47:1119–28.
- **Brynskov J, Foegh P, Pedersen G, et al.(2002):** Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. *Gut.* 51:37–43.
- **Capsoni F, Sarzi-Puttini P, and Atzeni F.(2005):** Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. *Arthritis Res Ther.* 7:R250–R255.
- **Carson KR, Evens AM, et al.(2009):** Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports (RADAR) Project. *Blood.* 113(20):4834–4840. Pre-published online as a Blood First Edition Paper on March 5, 2009. (Epub ahead of print).

- **Catrina AI, af Klint E, and Ernestam S.(2006):** Anti-tumor necrosis factor therapy increases synovial osteo-protegerin expression in rheumatoid arthritis. *Arthritis Rheum.* 54:76–81.
- **Catrina AI, Lampa J, and Ernestam S.(2002):** Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. *Rheumatology (Oxford).* 41:484–489.
- **Catrina AI, Trollmo C, and Af Klint E.(2005):** Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. *Arthritis Rheum.* 52:61–72.
- **Choy E, Hazleman B, and Smith M.(2002):** Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. *Rheumatology.* 41:1133–1137.
- **Choy EH, Panayi GS.(2001):** Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med.* 344:907–916.
- **Chung JH, Van Stavern GP, and Frohman LP, et al.(2006):** Adalimumab-associated optic neuritis. *J Neurol Sci.* 244(1–2):133–136. Epub 2006 Mar 9.
- **Clatworthy MR, Watson CJE, Plotnek G, et al.(2009):** B-Cell-Depleting Induction Therapy and Acute Cellular Rejection. *N Engl J Med.* 360:2683–5.
- **Colombel JF, Loftus WJ EV, and Tremaine LJ, et al.(2004):** The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. *Gastroenterology.* 126:19–31.

- **Comby E, Tanaff P, and Mariotte D.(2006):** Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with long term infliximab therapy. *J Rheumatol.* 33:24–30.
- **Cooper N, Stasi R, and Cunningham-Rundl, et al.(2004):** The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. *Br J Haematol* 125:232–239.
- **D’Haens G, Lemmens L, Geboes K, et al.(2001):** Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. *Gastroenterology.* 120:1323–1329.
- **Danese S, Sans M, and Scaldaferri F.(2006):** TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. *J Immunol.* 176:2617–2624.
- **Danese S, Scaldaferri F, Vetrano A, et al.(2007):** Critical role of CD40 CD40 ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease. *Gut.* 56:1248–1256.
- **Dass S, Rawstron AC, and Vital EM, et al.(2008):** Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. *Arthritis & Rheumatism.* 58:2993–9.
- **De Jager W, Velthuis and Rijkers G.(2003):** Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. *CDLI.* 10:133–139.
- **De Rycke L, Kruithof E, and Van Damme N.(2003):** Antinuclear antibodies following infliximab treatment in patients

with rheumatoid arthritis or spondylarthropathy. *Arthritis Rheum.* 48:1015–1023.

- **Den Broeder AA, Wanten GJ, and Oyen W.(2003):** Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha monoclonal antibody in patients with rheumatoid arthritis. *J Rheumatol.*30:232–237.
- **Dörner T, Isenberg D, and Jayne D, et al.(2009):** Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. *Autoimmunity Reviews.* In Press. Accepted Manuscript - doi:10.1016/j.autrev.
- **Dumont FJ.(2002):** IDEC-131. IDEC/Eisai. *Curr Opin Investig Drugs.* 3:725–734.
- **Ehrenstein MR, Evans JG, and Singh A.(2004):** Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. *J Exp Med.* 200:277–285.
- **Eriksson P (2005):** Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. *J Intern Med* 257:540–548.
- **Farrell JR, Peppercorn MA.(2002):** Ulcerative colitis. *Lancet.* 359:331–340.
- **Friedman S.(2004):** General principles of medical therapy of inflammatory bowel disease. *Gastroenterol Clin North Am.*33:191–208.
- **Furst D, Fleischmann R, and Kopp E, et al.(2005):** A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis. *J Rheumatol.*32:2303–2310.

- **Gallagher G, Eskdale J, and Bidwell J.(2003):** Cytokine genetics – polymorphisms, functional variations and disease associations. In: Thomson AW, Lotze MT, eds. The Cytokine Handbook, 4th ed. Boston: Academic Press. pp. 19–55.
- **Gelfand J M, Weinstein R, and Porter S B, et al.(2005):** Prevalence and treatment of psoriasis in the United Kingdom: a population - based study. Arch Dermatol. 141:1537–1541.
- **Gillies S, Lan Y, and Brunkhorst B, et al.(2002):** Bifunctional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer. Cancer Immunol Immunother. 51:449–460.
- **Gitter AH, Wullstein F, and Fromm M.(2001):** Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology. 121:1320–1328.
- **Goldring SR, Gravallesse EM.(2002):** Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep. 4:226–231.
- **Goldstein I, Ben-Horin S, and Koltakov A.(2007):** α 1 β 1 Integrin⁺ and regulatory Foxp3⁺ T cells constitute two functionally distinct human CD4⁺ T cell subsets oppositely modulated by TNF α blockade. J Immunol. 178:201–210.
- **Gomez-Reino JJ, Carmona L, and Angel Descalzo M.(2007):** Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 57:756–761.
- **Grewe M, Bruijnzeel-Koomen C, and Schopf E.(1998):** A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today. 19:339–361.

- **Hanauer S B.(2006):** Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. *Inflamm Bowel Dis.* 12(Suppl 1)S3–S9.
- **Hansen A, Lipsky PE, Dörner T (2005):** Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. *Curr Opin Rheumatol* 17:558–565.
- **Haraoui B, Cameron L, and Ouellet M.(2006):** Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. *J Rheumatol.* 33:31–36.
- **Harashima S, Horiuchi T, and Hatta N.(2001):** Outside-to-inside signal through the membrane TNF-alpha induces E expression on activated human CD4+ T cells. *J Immunol.* 166:130–136.
- **Hauser S, Waubant E, and Arnold D, et al.(2007):** A Phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS). In: American Academy of Neurology 59th annual meeting, Boston, April 28–May 5, 2007.
- **Hauser SL, Asbury AK.(2008):** Guillain-Barre syndrome and other immune-mediated neuropathies. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. *Harrison's Principles of Internal Medicine.* 17. I and II. New York: The McGraw-Hill Companies, Inc.; pp. 2667–2670.
- **Hauser SL, Goodin DS, and Fauci AS, et al.(2008):** Multiple sclerosis and other demyelinating diseases. editors. *Harrison's Principles of Internal Medicine.* 17. I and II. New York: The McGraw-Hill Companies, Inc; pp. 2611–2614.

- **Hauser SL, Ropper AH.(2008):** Diseases of the spinal cord. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. *Harrison's Principles of Internal Medicine*. 17. I and II. New York: The McGraw-Hill Companies, Inc; pp. 2592–2593.
- **Hauser SL.(2008):** Multiple Lessons for Multiple Sclerosis. *N Engl J Med*.359:1838–41.
- **Hawker K, O'Connor P, Freedman MS, et al.(2009):** Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. *Annals of Neurology*.9999:NA.
- **He MM, Smith AS, and Oslob JD, et al.(2005):** Small-molecule inhibition of TNF-alpha. *Science*. 310:1022–1025.
- **Hehlgans T, and Pfeer K.(2005):** The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. *Immunology*. 115:1–20.
- **Heidel F, Lipka DB, and von Auer C, et al.(2007):** Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. *Thromb Haemost* 97:228–233.
- **Hlavaty T, Pierik M, and Henckaerts L.(2005):** Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. *Aliment Pharmacol Ther*. 22:613–626.
- **Horton JC.(2008):** Disorders of the eye. In: Fauci AS, Braunwald E, Kasper DL, et al., editors. *Harrison's Principles of Internal Medicine*. 17. I and II. New York: The McGraw-Hill Companies, Inc.p. 187.

- **Hotchkiss R, Tinsley K, and Swanson P.(2001):** Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. *J Immunol.* 166:6952-6963.
- **House R.(2001):** Cytokine measurement techniques for assessing hypersensitivity. *Toxicology.* 158:51–58.
- **Hurlimann D, Forster A, and Noll G.(2002):** Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. *Circulation.* 106:2184–2187.
- **Ingham E.(2000):** Cytokines. In Adams AP, Cashman JN, eds. *Recent Advances in Anesthesia and Analgesia.* London: Churchill Livingstone. 21: 17-40.
- **Ioannou Y, Isenberg DA (2002):** Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. *Postgrad Med J* 78:599–606.
- **Itai T, Tanaka M, Nagata S.(2001):** Processing of tumor necrosis factor by the membrane-bound TNF-alpha-converting enzyme, but not its truncated soluble form. *Eur J Biochem.* 268:2074–2082.
- **Ito H, Takazoe M, Fukuda Y, et al.(2003):** Effective treatment of active Crohn's disease with humanized monoclonal antibody MRA to interleukin-6 receptor: a randomized placebo-controlled trial. *Gastroenterology.* 124:A25.
- **Janeway C, and Medzhitov R.(2002):** Innate immune recognition *Annu. Rev. Immunol.* 20,197-216.
- **Jones RB, Ferraro AJ, Chaudhry AN, et al.(2009):** A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis & Rheumatism.* 60:2156–68.

- **Kadar J, Petrovicz E (2004):** Adult-onset Still's disease. *Best Pract Res Clin Rheumatol* 18:663–676.
- **Kamar N, Mengelle C, Rostaing L.(2009):** Incidence of JC-Virus Replication After Rituximab Therapy in Solid-Organ Transplant Patients. *American Journal of Transplantation*. 9:244–5.
- **Kasahara S, Ando K, and Saito K.(2003):** Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. *J Virol*. 77:2469–2476.
- **Kaushik V, Moots R.(2005):** CDP-870 (certolizumab) in rheumatoid arthritis. *Expert Opin Biol Ther*. 5:601–606.
- **Kay J, Matteson E, and Dasgupta B, et al.(2005):** Subcutaneous Injection of CNTO 148 Compared with Placebo in Patients with Active Rheumatoid Arthritis Despite Treatment with Methotrexate: A Randomized, Double-blind, Dose-ranging Trial. American College of Rheumatology; San Diego.
- **Kaymakcalan SP, Bose S, Sasso EH.(2006):** Etanercept, infliximab, and adalimumab bind to soluble and transmembrane TNF with similar affinities. *Clin Immunol*.119(supplement):S69.
- **Keogh KA, Wylam ME, and Stone JH, et al. (2005):** Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 52:262–268.
- **Keystone EC, Emery P, Peterfy CG, et al.(2008):** Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. *Ann Rheum Dis*.ard.2007.085787.
- **Kirkwood J, Richards T, and Zarou H.(2002):** Immunomodulatory effects of high-dose and low-dose interferon

$\alpha 2b$ in patients with high-risk resected melanoma. *Cancer*. 95:1101-1112.

- **Klimiuk PA, Sierakowski S, and Domyslawska I.(2004):** Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. 52:36–42.
- **Klinkhoff A.(2004):** Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. *Drugs*.64:1267–1283.
- **Kosiewicz MM, Nast CC, and Krishnan A.(2001):** Th₁-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. *J Clin Invest*. 107:695–702.
- **Koukoulaki M, Smith KG, Jayne DR.(2006):** Rituximab in Churg–Strauss syndrome. *Ann Rheum Dis* 65:557–559.
- **Kozuch PL, Hanauer SB.(2006):** General principles and pharmacology of biologics in inflammatory bowel disease. *Gastroenterol Clin N Am*. 35:757–773.
- **Krishnan C, Kaplin AI, and Deshpande DM, et al.(2004):** Transverse myelitis: pathogenesis, diagnosis, and treatment. *Front Biosci*. 9:1483–1499.
- **Krueger G, Ellis C N.(2005):** Psoriasis – recent advances in understanding its pathogenesis and treatment. *J Am Acad Dermatol*. 53(Suppl 1)S94–100.
- **Leandro MJ, Cambridge G, and Edwards JC, et al.(2005):** B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. *Rheumatology (Oxford)* 44:1542–1545.

- **Levine TD (2005):** Rituximab in the treatment of dermatomyositis: an open-label pilot study. *Arthritis Rheum* 52:601–607.
- **Lew W, Bowcock A, and Kruege J.(2004):** Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and “Type 1” inflammatory gene expression. *Trends Immunol* 2004;25:295–305.
- **Lim W-C, Hanauer SB.(2004):** Emerging biologics therapies in inflammatory bowel disease. *Rev Gastroenterol Disord.*4:66–85.
- **Lima MA, Drislane FW, Koralnik IJ.(2006):** Seizures and their outcome in progressive multifocal leukoencephalopathy. *Neurology.* 66(2):262–264.
- **Lin J, Ziring D, and Desai S.(2007):** TNF α blockade in human diseases: an overview of efficacy and safety. *Clin Immunol.* doi: 10.1016/j.clim. 08.012. in press.
- **Lissauer M, Johnson S, and Siuzdak G.(2007):** Coagulation and Complement Protein Differences Between Septic and Uninfected Systemic Inflammatory Response Syndrome Patients. *Journal of Trauma-Injury Infection & Critical Care.* 62(5):1082-1094.
- **Lissauer M, Johnson S, and Field C, et al.(2007):** IL-1/tumor necrosis factor receptor gene expression characterizes sepsis in critically ill systemic inflammatory response syndrome patients. *Critical Care,* 11(Suppl 2):P449.
- **Loftus E V, Schoenfeld P, and Sandborn W J, et al.(2002):** The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. *Ailment Pharmacol Ther.* 1651–60.
- **Looney RJ, Anolik JH, and Campbell D, et al.(2004):** B cell depletion as a novel treatment for systemic lupus erythematosus: a

- **McFarland HF.(2008):** The B Cell -- Old Player, New Position on the Team. *N Engl J Med.* 358:664–5.
- **Meneses A, Verastegui E, and Barrera J.(2003):** Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2. *Int Immunopharmacol.* 3:1083–1091.
- **Mihai G, Jos W, and Kullberg B.(2003):** Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? *TRENDS in Immunology.* Vol.24 No.5 ;254-258.
- **Miwatashi S, Arikawa Y, and Kotani E, et al.(2005):** Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of [2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. *J Med Chem.* 48:5966–5979.
- **Mohan VP, Scanga CA, and Yu K.(2001):** Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. *Infect Immun.* 69:1847–1855.
- **Monneret G, Lepape A, and Voirin N.(2006):** Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. *Intensive Care Med* 32:1175–1183.
- **Mosmann T, Li L, and Sad S.(1997):** Functions of CD8 T-cell subsets secreting different cytokine patterns. *Semin Immunol.* 9:87–92.
- **Mugnier B, Balandraud N, and Darque A.(2003):** Polymorphism at position-308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. *Arthritis Rheum.* 48:1849–1852.

phase I/II dose-escalation trial of rituximab. *Arthritis Rheum* 50:2580–2589.

- **MacDonald TT, Monteleone G.(2001):** Interleukin-12 and Th1 immune responses in human Peyer's patches. *Trends Immunol.* 22:244–247.
- **Mamula P, Markowitz JE, and Cohen LJ, et al.(2004):** Infliximab in pediatric ulcerative colitis: two-year follow-up. *J Pediatr Gastroenterol Nutr.* 38:298–301.
- **Manjarrez-Orduno N, Quach TD, and Sanz I.(2009):** B Cells and Immunological Tolerance. *J Invest Dermatol.* 129:278–88.
- **Mannon PJ, Fuss IJ, Mayer L, et al.(2004):** Anti-interleukin-12 antibody for active Crohn's disease. *N Engl J Med.* 35:2069–2079.
- **Marini M, Bamias G, and Rivera-Nieves J.(2003):** TNF-alpha neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. *Proc Natl Acad Sci U S A.* 100:8366–8371.
- **Marinova-Mutafchieva L, Williams RO, and Mauri C.(2000):** A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis. *Arthritis Rheum.* 43:638–644.
- **Martin F, Chan AC.(2006):** B Cell Immunobiology in Disease: Evolving Concepts from the Clinic. *Annual Review of Immunology.* 24.
- **Mathey E, Pollard J, and Armati P.(2003):** In situ hybridization for cytokines in human tissue biopsies. *Methods Mol Biol.* 204:57–66.

- **Munford R, and Pugin J.(2001):** Normal responses to injury prevent systemic inflammation and can be immunosuppressive. *Am J Respir Crit Care Med.* 163:316-321.
- **Murphy P, Baggiolini M, and Charo I.(2000):** International union of pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol Rev.* 52:145–176.
- **Naldi L, Griffiths C E.(2005):** Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. *Br J Dermatol.* 152:597–615.
- **Ng KP, Cambridge G, and Leandro M, et al.(2007):** B cell depletion therapy in patients with systemic lupus erythematosus: long term follow up and predictors of response. *Ann Rheum Dis* 66(Suppl. II):56.
- **Nierhaus A, Montag B, and Timmler N.(2003):** Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. *Intensive care Med* 29:646–651.
- **Norton A, Roberts I (2006):** Management of Evans syndrome. *Br J Haematol* 132:125–137.
- **Noss EH, Hausner-Sypek DL, Weinblatt ME (2006):** Rituximab as therapy for refractory polymyositis and dermatomyositis. *J Rheumatol* 33:1021–1026.
- **O'Shea J, Ma A, and Lipsky P.(2002):** Cytokines and autoimmunity. *Nat Rev Immunol.* 2:37–45.
- **Oberholzer A, Oberholzer C, and Moldawer L.(2001):** Sepsis syndromes: understanding the role of innate and acquired immunity. *Shock.* 16:83-96.

- **Ogura Y, Bonen DK, Inohara N, et al.(2001):** A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. *Nature*. 411:603–606.
- **Omdal R, Wildhagen K, and Hansen T, et al.(2005):** Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. *Scand J Rheumatol* 34:229–232.
- **O'Neill SK, Liu E, Cambier JC.(2009):** Change you can B(cell)eive in: recent progress confirms a critical role for B cells in type 1 diabetes. *Curr Opin Endocrinol Diabetes Obes*.
- **Payen D, Faivre V, and Losser M.(2000):** Assessment of immunological status in the critically ill. *Minerva Anesthesiol* 66:351–357.
- **Penalver FJ, Jimenez-Yuste V, and Almagro M, et al.(2006):** Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. *Ann Hematol* 85:400–406.
- **Pero MMD, Chaudhry A, and Jones RB.(2009):** B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. *Clinical Otolaryngology*. 34:328–35.
- **Perrotta AL.(2006):** Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. *Clin Appl Thromb Hemost* 12:97–100.
- **Petit-Bertron A, Pedron T, and Gross, U.(2005):** Adherence modifies the regulation of gene expression induced by interleukin-10. *Cytokine* 29:1–12.

- **Pierik M, Vermeire S, and Steen KV.(2004):** Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. *Aliment Pharmacol Ther.* 20:303–310.
- **Pizarro TT, Arseneau KO, and Bamias G.(2003):** Mouse models for the study of Crohn's disease. *Trends Mol Med.* 9:218–222.
- **Plevy S.(2002):** The immunology of inflammatory bowel disease. *Gastroenterol Clin North Am.* 31:77–92.
- **Plevy SE, Salzberg BA, Reguiero M, et al.(2003):** A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: preliminary results of a phase I study. *Gastroenterology.* 124:A7.
- **Ramos-Casals M, Soto M, and Cuadrado M.(2009):** Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases. *Lupus.* 18:767–76.
- **Raptiva (PML 3rd Case) Dear Healthcare Provider letter.(2008):** Feb, 2008.
- **Richez C, Blanco P, and Lagueny A, et al.(2005):** Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. *Neurology.* 64(8):1468–1470.
- **Ringheanu M, Daum F, and Markowitz J.(2004):** Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. *Inflamm Bowel Dis.* 10:801–810.
- **Romagnani S.(1997):** The Th1/Th2 paradigm. *Immunol Today.* 18:263–266.
- **Roos KL, Tyler KL.(2008):** Meningitis, encephalitis, brain abscess, and empyema. In: *Fauci AS, Braunwald E, Kasper DL, et*

al., editors. *Harrison's Principles of Internal Medicine*. 17. I and II. New York: The McGraw-Hill Companies, Inc. pp. 2634–2635.

- **Rosenbloom A, Linden P, and Dorrance A, et al.(2005):** Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. *Chest* 127:2139–2150.
- **Ruiz-Jimeno T, Carvajal A, and Mata C, et al.(2006):** Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab. *J Rheumatol*. 33(7):1457–1458.
- **Rutgeerts P, Lemmens L, and Van Assche G, et al.(2003):** Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. *Aliment Pharmacol Ther*. 17:185–192.
- **Sandborn WJ, Feagan BG, and Hanauer SB, et al.(2001):** An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. *Gastroenterology*. 120:1330–1338.
- **Sandborn WJ, Yednock TA.(2003):** Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. *Am J Gastroenterol*. 98:2372–2382.
- **Sanz I.(2009):** The conundrum of B cell depletion in SLE. *Nature Reviews Rheumatology*. 5:304–5.
- **Schluns K, and Lefrancois L.(2003):** Cytokine control of memory T-cell development and survival. *Nat Rev*. 3:269–279.

- **Schneemilch C, and Bank U.(2001):** Pro and anti-inflammatory cytokine release in plasma of patients under different anesthetic techniques. *Anaesthesiol Reanimat.* 26; 1: 4 -10.
- **Schollkopf C, Kjeldsen L, and Bjerrum OW, et al.(2006):** Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. *Leuk Lymphoma* 47:253–260.
- **Schreiber S, Khaliq-Kareemi M, and Lawrence I, et al.(2005):** Certolizumab pegol, a humanised anti-TNF PEGylated Fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's Disease: a Phase III study (PRECISE) (Abstract) *Gut.* 54:A82.
- **Schreiber S, Rutgeerts P, and Fedorak R N, et al.(2005):** CDP870 Crohn's Disease Study Group. A randomized, placebo - controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. *Gastroenterology.* 129:807–818.
- **Scully M, Cohen H, and Cavenagh J, et al.(2007):** Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. *Br J Haematol* 136:451–461.
- **Seitz M, Wirthmuller U, and Moller B.(2007):** The-308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. *Rheumatology (Oxford)* 46:93–96.
- **Sellner J, Lüthi N, and Schüpbach WM, et al.(2009):** Diagnostic workup of patients with acute transverse myelitis: spectrum of clinical presentation, neuroimaging, and laboratory findings. *Spinal Cord.* 47(4):312–317.

- **Seror R, Sordet C, and Guillevin L, et al.(2007):** Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. *Ann Rheum Dis* 66:351–357.
- **Shanahan F.(2002):** Crohn's disease. *Lancet*. **359**:62–69.
- **Sheera P, and Hall G.(1997):** Cytokines in Anesthesia. *British Journal of Anesthesia*. 78 : 201-219.
- **Shen C, Assche GV, and Colpaert S.(2005):** Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. *Aliment Pharmacol Ther*. 21:251–258.
- **Shen C, Maerten P, and Geboes K.(2005):** Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. *Clin Immunol*. 115:250–259.
- **Shin IS, Baer AN, and Kwon HJ, et al.(2006):** Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. *Arthritis Rheum*. 54(5):1429–1434.
- **Siegmund B, Fantuzzi G, Rieder F, et al.(2001):** Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN- γ gamma and TNF-alpha production. *Am J Physiol Regul Integr Comp Physiol*. **281**:R1264–R1273.
- **Sieper J, Baraliakos X, and Listing J.(2005):** Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. *Rheumatology (Oxford)* 44:1525–1530.
- **Smith KG, Jones RB, and Burns SM, et al.(2006):** Long-term comparison of rituximab treatment for refractory systemic lupus

erythematosus and vasculitis: remission, relapse, and re-treatment. *Arthritis Rheum* 54:2970–2982.

- **Smith KGC, Jones RB, and Burns SM.(2006):** Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. *Arthritis & Rheumatism*. 54:2970–82.
- **Smith SH, Tedder TF.(2009):** Targeting B-cells Mitigates Autoimmune Diabetes in NOD Mice: What Is Plan B? *Diabetes*. 58:1479–81.
- **Smolen JS, Emery P, Keystone EC, et al.(2006):** Consensus Statement on the Use of Rituximab in Patients With Rheumatoid Arthritis. *Ann Rheum Dis*. ard.2006.061002.
- **Sole K.(2006):** Pegsunercept is a safe and efficacious treatment for rheumatoid arthritis. *Nat Clin Pract Rheumatol*. 2:121.
- **Spencer-Green G.(2000):** Etanercept (Enbrel): update on therapeutic use. *Ann Rheum Dis*. 59:i46–i49.
- **Sperr WR, Lechner K, Pabinger I (2007):** Rituximab for the treatment of acquired antibodies to factor VIII. *Haematologica* 92:66–71.
- **Stasi R, Stipa E, and Del Poeta G, et al.(2006):** Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. *Rheumatology (Oxford)* 45:1432–1436.
- **Takemura S, Klimiuk P A, and Braun A, et al.(2001):** T cell activation in rheumatoid synovium is B cell dependent. *J Immunol*. 167:4710–4718.

- **Tamura N, Matsudaira R, and Hirashima M, et al.(2007):** Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. *Intern Med* 46:409–414.
- **Tatsumi T, Kierstead L and Ranieri E.(2002):** Disease-associated bias in T helper type 1 (Th1)/Th2 CD4+ T-cell responses against MAGE-6 in HLADRB1*0401+ patients with renal cell carcinoma or melanoma. *J Exp Med.* 196:619–628.
- **Taylor PC, Peters AM, and Paleolog E.(2000):** Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. *Arthritis Rheum.* 43:38–47.
- **Taylor RP, Lindorfer MA.(2007):** Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. *Nat Clin Pract Rheumatol.* 3:86–95.
- **Ten Hove T, van Montfrans C, and Peppelenbosch MP. (2002):** Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. *Gut.* 50:206–211.
- **Tetta C, Bellomi R, and Ronco C.(2000):** Endotoxin and cytokine removal in sepsis. *Ther Apher.* Volume 6, NO.2; 109-115.
- **Thurlings RM, Vos K, and Gerlag DM.(2008):** Disease activity-guided rituximab therapy in rheumatoid arthritis: The effects of re-treatment in initial nonresponders versus initial responders. *Arthritis & Rheumatism.* 58:3657–64.
- **Till A, Rosenstiel P, and Krippner-Heidenreich A.(2005):** The Met-196→Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. *J Biol Chem.* 280:5994–6004.

- **Tokunaga M, Saito K, and Kawabata D, et al.(2007):** Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. *Ann Rheum Dis* 66:470–475.
- **Trappe R, Loew A, and Thuss-Patience P, et al.(2006):** Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. *Ann Hematol* 85:134–135.
- **Ulfgren AK, Andersson U, and Engstrom M.(2000):** Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. *Arthritis Rheum.* 43:2391–2396.
- **Ulloa L, and Tracey K.(2005):** The cytokine profile: a code for sepsis. *Trends Mol Med.* 11:56–62.
- **Ulrich P, Grenet O, and Bluemel J.(2001):** Cytokine expression profiles during murine contact allergy: T helper 2 cytokines are expressed irrespective of the type of contact allergen. *Arch Toxicol* 2001;75:470–479.
- **van Assche G, Dalle I, Noman M, et al.(2003):** A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. *Am J Gastroenrol.* 98:369–376.
- **van Assche G.(2007):** Emerging drugs to treat Crohn's disease. *Expert Opin Emerging Drugs.*12:49–59.
- **van Deventer SJH.(2002):** A place for TACE. *Gut.* 51:5–6.

- **Tokunaga M, Saito K, and Kawabata D, et al.(2007):** Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. *Ann Rheum Dis* 66:470–475.
- **Trappe R, Loew A, and Thuss-Patience P, et al.(2006):** Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. *Ann Hematol* 85:134–135.
- **Ulfgren AK, Andersson U, and Engstrom M.(2000):** Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. *Arthritis Rheum.* 43:2391–2396.
- **Ulloa L, and Tracey K.(2005):** The cytokine profile: a code for sepsis. *Trends Mol Med.* 11:56–62.
- **Ulrich P, Grenet O, and Bluemel J.(2001):** Cytokine expression profiles during murine contact allergy: T helper 2 cytokines are expressed irrespective of the type of contact allergen. *Arch Toxicol* 2001;75:470–479.
- **van Assche G, Dalle I, Noman M, et al.(2003):** A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. *Am J Gastroenrol.* 98:369–376.
- **van Assche G.(2007):** Emerging drugs to treat Crohn's disease. *Expert Opin Emerging Drugs.*12:49–59.
- **van Deventer SJH.(2002):** A place for TACE. *Gut.* 51:5–6.

- **Wiik A (2003):** Autoantibodies in vasculitis. *Arthritis Res Ther* 5:147–152.
- **Williams RO, Marinova-Mutafchieva L, and Feldmann M.(2000):** Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy. *J Immunol.* 165:7240–7245.
- **Wong CF.(2007):** Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence? *Nephrol Dial Transplant* 22:32–36.
- **Wood KL, Hage CA, and Knox KS.(2003):** Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. *Am J Respir Crit Care Med.*167:1279–1282.
- **Yomtovian R, Niklinski W, and Silver B, et al.(2004):** Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. *Br J Haematol* 124:787–795.
- **Youinou P, Renaudineau Y (2004):** The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases. *Thromb Res* 114:363–369.
- **Yousry TA, Major EO, and Ryschkewitsch C, et al.(2006):** Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. *N Engl J Med.* 354(9):924–933.
- **Zaja F, Vianelli N, and Battista M, et al.(2006):** Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. *Exp Hematol* 34:571–572.
- **Zeissig S, Bojarski C, and Buerge N.(2001):** Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by

tumour necrosis factor alpha antibody treatment. Gut. 53:1295–1302.

- **Zeltser R, Valle L, and Tanck C.(2001):** Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol. 137:893–899.
- **Zlotnik A, and Osamu Y.(2000):** Chemokines: a new classification system and their role in immunity. Immunity. 12:121–127.